Evidence map›Paper›PMID 42028286›Full record

ArticleMaterials today. Bio2026

Enhancing exosomes efficacy with engineered nanozymes for a multi-targeted combination strategy in osteoarthritis treatment.

Chenyue Xu, Zhengyi Ni, Qi Wang, Handi Li, Lie Wu, Yuhang Shi, Xiaobo Chen, Ziyi Li, Huijun Kang, Yanxin Liu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chenyue XuHebei Medical University Clinical Medicine Postdoctoral Station (Hebei Medical University Third Hospital), Shijiazhuang, Hebei, 050051, China.
Zhengyi NiDepartment of Joint Surgery, Hebei Province Sino-US International Joint Research Center for Bone and Joint Diseases, Hebei Province Joint Degeneration and Sports Injury Technology Innovation Center, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, 050051, China.
Qi WangDepartment of Orthopaedic Surgery, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China.
Handi LiDepartment of Joint Surgery, Hebei Province Sino-US International Joint Research Center for Bone and Joint Diseases, Hebei Province Joint Degeneration and Sports Injury Technology Innovation Center, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, 050051, China.
Lie WuState Key Laboratory of Advanced Refractories, Wuhan University of Science & Technology, Wuhan, 430081, China.
Yuhang ShiDepartment of Joint Surgery, Hebei Province Sino-US International Joint Research Center for Bone and Joint Diseases, Hebei Province Joint Degeneration and Sports Injury Technology Innovation Center, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, 050051, China.
Xiaobo ChenDepartment of Joint Surgery, Hebei Province Sino-US International Joint Research Center for Bone and Joint Diseases, Hebei Province Joint Degeneration and Sports Injury Technology Innovation Center, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, 050051, China.
Ziyi LiDepartment of Joint Surgery, Hebei Province Sino-US International Joint Research Center for Bone and Joint Diseases, Hebei Province Joint Degeneration and Sports Injury Technology Innovation Center, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, 050051, China.
Huijun KangDepartment of Joint Surgery, Hebei Province Sino-US International Joint Research Center for Bone and Joint Diseases, Hebei Province Joint Degeneration and Sports Injury Technology Innovation Center, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, 050051, China.
Yanxin LiuDepartment of Bioengineering, University of California, Los Angeles, CA, 90095, United States.
Zeyu LiuCenter for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, 13353, Germany.
Fei WangDepartment of Joint Surgery, Hebei Province Sino-US International Joint Research Center for Bone and Joint Diseases, Hebei Province Joint Degeneration and Sports Injury Technology Innovation Center, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, 050051, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by multifactorial pathological mechanisms, and remains a significant clinical challenge. Exosome therapy represents a future direction for delaying OA progression, yet its efficacy is often compromised by inflammatory microenvironment within the joints. To overcome these limitations, we present a novel combinatorial therapeutic platform that alleviates OA through a multi-targeted strategy, including the scavenging of reactive oxygen species (ROS), suppression of macrophage-driven inflammation, and inhibition of chondrocyte ferroptosis. This platform combines dental pulp stem cells-derived exosomes (Exo) with hollow mesoporous cerium oxide nanozymes, which were first loaded with curcumin and subsequently coated with hyaluronic acid, termed HA@Cur@CeO

Indexed as

ExosomesFerroptosisMicroenvironment remodelingNanozymesOsteoarthritis

Identifiers

PMID42028286
PMCPMC13101615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.